Compare VanEck Junior Gold Miners (GDXJ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Junior Gold Miners vs State Street SPDR S&P Biotech ETF — how do they compare? VanEck Junior Gold Miners trades at $114.32 (market cap $8.22B), while State Street SPDR S&P Biotech ETF trades at $153.72 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, VanEck Junior Gold Miners nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Junior Gold Miners for 41 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| GDXJ | XBI | |
|---|---|---|
Market Cap | $8.22B | $10.11B |
Volume | 3,212,198 | 12,903,266 |
Sector | Commodities - Metals/Agriculture | Broad Market / Factor |
52-Week High | $156.19 | $169.55 |
52-Week Low | $87.56 | $104.99 |
Typical Hold Time | 41 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDXJ, the VanEck Junior Gold Miners ETF, trades at $114.39, up 4.81% in the last 24 hours. The technical outlook is bearish, with moving averages and key indicators like ADX signaling selling pressure. Recent news highlights multiple junior gold mining companies being added to the ETF's underlying index, potentially increasing its diversification and appeal. However, key financial ratios such as P/E and P/S are unavailable for direct analysis of the ETF's valuation.
The outlook for GDXJ is mixed, balancing recent index additions against a bearish technical backdrop. Investment opportunities lie in exposure to junior gold miners amid high gold prices, but risks include sector volatility and the ETF's current negative momentum. Investors should weigh the potential for broader market recognition against prevailing selling pressure.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
